A toxicity study of eltenac, a nonsteroidal anti-inflammatory drug, in horses.
Abstract: A double-blind study was performed, in horses, to determine the potential toxic effects of the nonsteroidal anti-inflammatory drug, eltenac(4-[(2,6-dichlorophenyl) amino]-3-thiopheneacetic acid). Four treatment groups of six horses were formed. The drug was injected intravenously, once daily, at a dose level of 0.5 mg/kg, 1.5 mg/kg or 2.5 mg/kg for 15 days. A control group was injected with sterile saline solution. Horses were monitored for changes in appetite, physical examinations, biochemical evaluations and gastroscopic examinations. Complete post-mortem examinations were also performed. A few glandular gastric ulcers, mild in severity, developed in seven animals during the treatment period. This occurred more often in horses treated with high doses of eltenac (P = 0.02). A dose-dependent change of white blood cell (WBC) count and neutrophil count was noted. Total protein, albumin and globulin levels had dose-dependent decreases. One horse in the high dose group (2.5 mg/kg) developed ventral ooedema as well as hypoproteinaemia. Gross post-mortem and histological examination did not reveal any signs of drug related gastrointestinal, renal or hepatic abnormalities. Toxic effects of eltenac given intravenously were greatest in horses treated with 2.5 mg/kg of the compound for 15 days compared to other groups.
Publication Date: 1998-03-21 PubMed ID: 9507454DOI: 10.1046/j.1365-2885.1998.00813.xGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The study conducted toxicity testing on the use of eltenac, a nonsteroidal anti-inflammatory drug, in horses, discovering that at higher doses it led to the development of gastric ulcers and changes in white blood cell count.
Study Overview
- This research aimed to understand the toxicity effects of a nonsteroidal anti-inflammatory drug called eltenac on horses. Eltenac is an anti-inflammatory drug often used to control pain and inflammation related symptoms in nonhuman subjects.
- The double-blind study was conducted on 24 horses divided into four groups of six. A method called double-blind was used for objectivity where neither the researcher nor the subjects (in this case, the caretakers) know which group receives the drug and which one gets a placebo.
Procedure and Dosage
- The horses were administered eltenac through intravenous injection at three different dosage levels — 0.5 mg/kg, 1.5 mg/kg, and 2.5 mg/kg of their weight. These doses were given once daily for a span of 15 days.
- A control group was also set up which was injected with a sterile saline solution to make comparative assessments of the drug’s impact.
Observations and Monitoring
- The horses were closely observed for any change in appetite, physical changes, biochemical evaluations, and gastroscopic examinations were also carried out.
- The study involved post-mortem examinations on all subjects to get detailed insights into the effects of eltenac.
- Gastric ulcers, although mild, were noticed in seven animals, especially those that received higher doses of eltenac.
- A change in white blood cell count and neutrophil count was also noticed, which was contingent upon the dosage of the drug given.
Results
- The study notes a dose-dependent decrease in total protein, albumin, and globulin levels.
- One horse that received the highest dose (2.5 mg/kg) developed ventral edema (swelling along the underside of the belly), as well as hypoproteinemia (low levels of protein in the blood).
- No evidence of drug-related gastrointestinal, renal, or liver abnormalities were found upon gross post-mortem and histological examination.
- The toxicity effects of eltenac were greatest in the group treated with 2.5 mg/kg of the drug for 15 days.
Cite This Article
APA
Goodrich LR, Furr MO, Robertson JL, Warnick LD.
(1998).
A toxicity study of eltenac, a nonsteroidal anti-inflammatory drug, in horses.
J Vet Pharmacol Ther, 21(1), 24-33.
https://doi.org/10.1046/j.1365-2885.1998.00813.x Publication
Researcher Affiliations
- Marion duPont Scott Equine Medical Centre, Virginia Maryland Regional College of Veterinary Medicine, Virginia Tech., Leesburg 22075, USA.
MeSH Terms
- Aniline Compounds / blood
- Aniline Compounds / pharmacokinetics
- Aniline Compounds / toxicity
- Animals
- Anti-Inflammatory Agents, Non-Steroidal / blood
- Anti-Inflammatory Agents, Non-Steroidal / pharmacokinetics
- Anti-Inflammatory Agents, Non-Steroidal / toxicity
- Appetite / drug effects
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Horses
- Injections, Intravenous
- Leukocyte Count / drug effects
- Male
- Mouth / drug effects
- Mouth / pathology
- Orchiectomy
- Stomach / drug effects
- Stomach / pathology
- Stomach Ulcer / chemically induced
- Thiophenes / blood
- Thiophenes / pharmacokinetics
- Thiophenes / toxicity
Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists
